2021 Symposium Topics:

  • Gastrointestinal NETS
  • Multiple NETs
  • Pheochromocytoma and Paraganglioma
  • Pancreatic NETs
View 2021 Agenda
View 2021 Posters

SESSION 1: Gastrointestinal NETs

Ramesh Shivdasani,
MD, PhD
Dana-Farber Cancer Institute

Anil Rustgi, MD
Columbia University

Presentations
  1. Rare Cancer Initiative Effort: A Roadmap For Neuroendocrine Tumor Dependency
    Moony (Yuen-Yi) Tseng, PhD, Broad Institute (Eli and Edythe L. Broad Institute of MIT and Harvard)
  2. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors
    Netta Mäkinen, PhD, Dana-Farber Cancer Institute
  3. Metabolomic Profile of Gastrointestinal and Pulmonary Neuroendocrine Tumors: Prognostic and Biological Relevance
    Anna La Salvia, MD, Hospital Universitario 12 de Octubre
  4. Nanobody-directed CAR T cells eliminate neuroendocrine tumors without toxicity via masking of the antigen target in normal cells
    Xianxin Hua, MD, PhD, University of Pennsylvania

SESSION 2: Multiple NETs

Lisa Bodei, MD, PhD
Memorial Sloan Kettering Cancer Center

George Fisher, MD
Stanford University

Presentations
  1. Biodistribution and radiation dosimetry of 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors
    Simone Krebs, MD, Memorial Sloan Kettering Cancer Center
  2. Multimodal analogs of DOTA-JR11 to investigate the unexpected bone marrow toxicity in NET patients
    Susanne Kossatz, PhD, Technical University Munich
  3. Engineering Decreased Nephrotoxicity for SSTR2 Targeted Alpha Therapy
    David Morse, PhD, H. Lee Moffitt Cancer Center & Research Institute
  4. uPAR-targeted PRRT: new radionuclide-based therapy
    Andreas Kjaer, MD, PhD, Copenhagen University Hospital (Rigshospitalet)
  5. Digital Image Analysis in Neuroendocrine Tumors
    Michelle Kim, MD, PhD, Icahn School of Medicine at Mount Sinai
  6. SV2A PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Neuroendocrine Tumors
    Guiyang Hao, PhD, UT Southwestern Medical Center
  7. SSTR2-targeted delivery of temozolomide
    Solmaz Aghaamiri, The University of Texas Health Science Center at Houston

SESSION 3: Pheo/Para & Lung NETs

Daniel M. Halperin, MD
MD Anderson Cancer Center

Dr Gay

Carl M. Gay, MD
MD Anderson Cancer
Center

Presentations
  1. Succinate accumulation is not sufficient for tumorigenesis in mouse chromaffin cells but dual loss of SDHB and NF1 yields SDHx-like pheochromocytomas
    Justin Annes, MD, PhD, Stanford University
  2. Adverse effects of oxygen in a cell culture model for SDHB-mutated Pheochromocytoma/Paraganglioma
    Arthur Tischler, MD, Tufts Medical Center
  3. First PET Imaging Studies with 3-[18F]fluoro-p-hydroxyphenethylguanidine ([18F]3F-PHPG) in Paraganglioma and Pheochromocytoma Patients
    David Raffel, MD, The Regents of the University of Michigan
  4. Organoid Models of Normal and Malignant Neuroendocrine Cells Reveal Pathways Important for Neuroendocrine Cell Growth, Differentiation, and Transformation
    Talya Dayton, PhD, Hubrecht Institute of Developmental Biology and Stem Cell Research
  5. Tumor xenografts in zebrafish: a new in vivo model for lung carcinoids
    Giovanni Vitale, MD, PhD, Istituto Auxologico Italiano

SESSION 4: Pancreas NETs

James Bibb, PhD
University of Alabama-Birmingham

Dawn Quelle, PhD
University of Iowa

Presentations
  1. Patient-derived Islet-like Tumoroids reflect phenotypic landscape of original Pancreatic Neuroendocrine Neoplasms and facilitate in vitro drug screening
    Simon L. April-Monn, University of Bern (Universität Bern)
  2. RABL6A-Myc signaling promotes pancreatic neuroendocrine tumor cell proliferation and survival
    Ume Salma Shaik Amjad, PhD, The University of Iowa
  3. Loss of MEN1 function inhibits DNA repair capability of pancreatic neuroendocrine tumors
    Xavier Keutgen, MD, The University of Chicago
  4. Loss of Men1 and Pten promotes invasion and metastasis of pancreatic neuroendocrine tumors
    Ziqiang Yuan, MD, Rutgers University Foundation
  5. The Importance of DDR genes in Response to PRRT- Evidence for PARP and DNA-PK as
    Therapeutic Targets to Increase Efficacy
    Rodney Hicks, MD, Peter MacCallum Cancer Centre
  6. Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
    Minah Kim, PhD, Columbia University Medical Center
  7. The role of the B7x signaling pathway in the development and progression of neuroendocrine tumors
    Steven Libutti, MD, Rutgers, The State University of New Jersey

Date

November 17-18, 2020

Location

Norton’s Woods Conference Center
American Academy of Arts & Sciences
136 Irving St, Cambridge, MA 02138